Myeloablative conditioning regimens for AML allografts: 30 years later. - Wikidata - wikimedia - TriplyDB

Myeloablative conditioning regimens for AML allografts: 30 years later.

Myeloablative conditioning regimens for AML allografts: 30 years later.

http://www.wikidata.org/entity/Q35574536

about

Management of patients with hepatitis B who require immunosuppressive therapy Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice.Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.Complications of allogeneic hematopoietic stem cell transplantation.Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report.Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison.High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation.High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia.Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors.Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India.Hepatic veno-occlusive disease associated with immunosuppressive cyclophosphamide dosing and roxithromycin.

P2860

Q26853490-0D4B3145-57A1-4235-BE97-E8CE3F7951E3 Q34463645-27C90EBD-41BF-4289-96FF-7DC8CA13DC7F Q35085078-5ADF1587-8ADE-4F42-88BD-074FCF9B921A Q35784905-4C8A5556-3E1E-4A56-9693-ED9D1DB4E51B Q37370649-9ADA7FEE-A0E8-4FE4-A58D-241418E53E95 Q38217938-E82FAA9B-F856-49C0-BBB0-B282CE92B1A2 Q38690071-A09C1686-C1D8-4C0E-BBD8-0A55BE74E19A Q42060470-F5BD49F1-D287-4BE0-80FF-397C91A24B22 Q44043143-BFAC8FC3-8CCF-4EA9-95F2-91E461ABB4D7 Q45001844-33644847-9FD1-40B0-BF66-6BECB2365235 Q45233938-4BD003C3-F8C6-4982-8EBE-9CE75565FBE0 Q46485581-8E51A088-B5ED-4335-93BA-CD2029DF7636 Q47135533-C109CEC0-BC1F-4789-A868-2876F41A35DE Q53628874-AA2035F8-FF0B-45CE-AAE3-1E212D0AD564

P2860

Myeloablative conditioning regimens for AML allografts: 30 years later.

http://www.wikidata.org/entity/Q35574536

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Myeloablative conditioning regimens for AML allografts: 30 years later.

@ast

Myeloablative conditioning regimens for AML allografts: 30 years later.

@en

type

label

Myeloablative conditioning regimens for AML allografts: 30 years later.

@ast

Myeloablative conditioning regimens for AML allografts: 30 years later.

@en

prefLabel

Myeloablative conditioning regimens for AML allografts: 30 years later.

@ast

Myeloablative conditioning regimens for AML allografts: 30 years later.

@en

P1433

Q35574536-B901F4EC-2F7B-45D0-8C10-152F3C356268

P1476

Q35574536-B01033A2-FCC4-4C61-AFDA-4D66B0D9E680

P2093

Q35574536-5DF00E34-F936-4980-982A-1A3FD1827092

Q35574536-6D9BA223-BEA0-4559-B6B2-116421FACD1C

Q35574536-B88CDACF-8927-4F95-A526-D1BFB717E12F

P2860

Q35574536-03BCD717-E249-4995-A884-314EF2917DFC

Q35574536-143F68B4-7B5C-4D68-8608-B640499DC553

Q35574536-17988A8C-5CD8-4F8D-9560-DF75FC7BD5D0

Q35574536-1F876B5F-F935-49E4-99EA-A62B3176F760

Q35574536-1FD4BC0C-E88F-45C6-94EF-7406C729FDDE

Q35574536-2FA51473-9BD7-4657-9550-C864B0164102

Q35574536-31289565-7035-4165-9AE9-5C981130373E

Q35574536-36D34443-5979-4B58-B167-AE5B6FA1B62E

Q35574536-3DD0ED6A-E8CF-4B18-9896-4379290A42A9

Q35574536-65CE5937-BE90-4C41-A413-30E36A1FEAE1

P2888

Q35574536-9C2F4450-241C-4DE9-950C-976F287B2C0E

P304

Q35574536-CCD0AE25-717D-46E0-BD7A-27544E89B1A3

P31

Q35574536-9AECAE71-F000-43A5-81B3-338F48271C67

P356

Q35574536-DAD11F46-BFD0-487B-8556-C4A488E5E7A0

P407

Q35574536-0E2ED799-0F79-4496-8532-AA46C3E32A31

P433

Q35574536-A4A3735B-5543-431B-9ABD-D85528C5A8E6

P478

Q35574536-A4542B8F-69E7-4F73-82D6-1FB9C7A57605

P577

Q35574536-97154669-84D7-4BE7-9D5E-AD33BC0FDF7B

P5875

Q35574536-0AF5D6FF-4B0E-4564-91C7-1562380BC4D7

P698

Q35574536-1592CAFD-903C-4765-9C6E-C9624B9C55D4

P356

P1433

Bone Marrow Transplantation

P1476

Myeloablative conditioning regimens for AML allografts: 30 years later.

@en

P2093

Gupta V

http://www.w3.org/2001/XMLSchema#string

Keating A

http://www.w3.org/2001/XMLSchema#string

Lazarus HM

http://www.w3.org/2001/XMLSchema#string

P2860

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

Marrow transplantation for acute nonlymphoblastic leukemic in first remission using fractionated or single-dose irradiation

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission

Marrow transplantation for acute nonlymphoblastic leukemia in first remission

A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation.

Is there a best transplant conditioning regimen for acute myeloid leukemia?

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st century.

The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial.

P2888

P304

969-978

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BMT.1704285

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

9029208

http://www.w3.org/2001/XMLSchema#string

P698

14595384

http://www.w3.org/2001/XMLSchema#string